Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on X:
“Happening Now.
Dana-Farber’s Breast Oncology Center and Dr. Waks debates standard of care in Stage II/III Her2+ Breast Cancer. Carboplatin addition to taxane HP does not improve pCR. EFS data still outstanding.
Neuropathy worse with weekly abraxane, HP for 18 weeks than TCHP.
What about Compass pCR? 12 weeks of taxane + HP in Stage II HER2+ BC.
pCR 43.8% overall: 63.7% ER-/HER2+, 32.5% ER+, HER2+.
Lower pCR rate with docetaxel versus weekly paclitaxel. EFS data is outstanding. No practice changing yet.
How many cycles 4 versus 6?
More cycles TCHP, higher pCR in TRAIN-3″
More posts featuring Sarah Sammons.
